Testing Active Surveillance for Hormone-Positive DCIS After Surgery
Treatments studied
Part of Cancer clinical trials.
This trial tests whether active surveillance (close monitoring) is a good option for certain patients with hormone-positive DCIS who have positive surgical margins after initial surgery. You would receive no immediate additional treatment—just regular imaging and check-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and at least 18 years old.
- You have been diagnosed with hormone-receptor-positive ductal carcinoma in situ (DCIS), meaning at least half of the cells tested for estrogen or progesterone receptors were positive. This includes cases with or without tiny invasive spots (microinvasion).
- You had surgery for DCIS and still have cancer cells at the edges of the removed tissue (positive margins) that haven't been removed again.
- You are not pregnant or breastfeeding, and you agree to use effective birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether taking hormone medicine before surgery can change the surgical plan and outcomes for people with extensive ductal carcinoma in situ (DCIS). It is for estrogen-receptor positive DCIS and aims to see how this “neoadjuvant” approach affects treatment decisions.
This trial tests a vaccine that targets a protein (MUC1) found in early breast cancer cells. It's for women with ER+ DCIS who are planning surgery, to see if the vaccine can help prevent the cancer from coming back or getting worse.
This trial tests a new drug called CAN1012 in people with pre-cancerous breast conditions called DCIS or LCIS. It aims to see if the drug can help before invasive cancer develops.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment. If found, participants receive new drug combinations to try to prevent cancer from returning.
This study is looking at whether it is safe for younger women who have had surgery for a very early-stage, low-risk breast condition called DCIS to skip radiation therapy. The goal is to see if they can avoid the side effects of radiation without the cancer coming back.
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Hear when a new Ductal Carcinoma in Situ trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.